Acrivon Therapeutics

Founder‑CEO Peter Blume‑Jensen, M.D., Ph.D., is the inventor of AP3 and OncoSignature and has deep oncology R&D experience at major pharma and prior diagnostics leadership, aligning expertise with the company’s strategic edge. The team has advanced two clinical programs and built an internal CLIA lab.

Governance watch‑items include ongoing equity compensation expansion typical of the sector. Net, we view management as scientifically strong and execution‑focused, with incentives aligned to clinical success.